$40.66
Above FV▼ -48.3% against the close used
Model range $16.98 – $97.35
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear$16.98Fair value$40.66Bull$97.35
FairClose
52-week traded range
52W low $59.0052W high $93.16
The 52-week range is measured from the stored price history, not estimated.
Trading above the consensus fair value
U.S. Physical Therapy, Inc. closed at $78.72, 93.6% above the consensus fair value of $40.66 drawn from 9 valuation models.
Financial DNA score 40/100 — Average. P/E of 55.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
$43.43
-44.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
$30.87
-60.8%
√(22.5 × EPS × BVPS)
EPS=1.42, BVPS=29.82 · outside Graham range (P/E 55.4, P/B 2.6) — asset-light, treat as a rough floor
P/E Fair Value
$28.40
-63.9%
EPS × 20x (sector P/E)
EPS=1.42, Sector P/E=20x
Peter Lynch (PEG)
$16.98
-78.4%
EPS × Growth% (PEG = 1 is fair)
EPS=1.42, g=12%
EV/EBITDA
$57.97
-26.4%
(EBITDA × 16x − Net Debt) ÷ Shares
EBITDA=109.07M
Dividend Discount (DDM)
$97.35
+23.7%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=1.8, r=10%, g=8%
Book Value (P/B)
$21.02
-73.3%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=29.82, ROE=8.8%, g=6%, r=10%
Reverse DCF
$78.72
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 20.9% | Historical: 12%
Margin of Safety
$25.67
-67.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=34.23, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.